David Shin, MD

Chief Strategy Officer

David Shin is the Chief Strategy Officer of Kriya Therapeutics. Previously, Dr. Shin was the Chief Operating Officer of Limelight Bio, a gene therapy company developing multiple technology platforms to address the limitations of viral vectors. Before Limelight, he helped start Alpine Biosciences to develop a nanotechnology platform for large molecule delivery, which was sold to Oncothyreon, a publicly traded oncology company. Prior to Alpine, Dr. Shin was a founding investment professional at Ayer Capital, a healthcare-specific hedge fund, where he managed investments in all subsectors of healthcare. He began his business career as a technology leader in multiple scientific software and device companies serving the biopharmaceutical industry, one of which was sold to Thermo Fisher Scientific where he remained as Director of Technology.

Dr. Shin received his Medical Degree from the University of Pennsylvania School of Medicine and his undergraduate degree in Electrical Engineering from Carnegie Mellon University.